Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Awakn Life Sciences Corp
(OP:
AWKNF
)
0.0800
UNCHANGED
Streaming Delayed Price
Updated: 11:38 AM EST, Nov 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Awakn Life Sciences Corp
< Previous
1
2
3
4
5
Next >
MDMA News: Exclusive Supply Deal With Awakn Life Sciences & Canadian Company Expands Psychedelics Production
March 02, 2023
PharmAla To Be Exclusive MDMA Supply Partner To Awakn Life Sciences Effective immediately, MDXX class molecules producer PharmAla Biotech Holdings Inc. will become the exclusive MDMA supplier to Awakn...
Via
Benzinga
Latest Psychedelics Deals: Optimi Supplies Australia, Awakn Partners Licensing In California
March 02, 2023
Optimi Health Enters Australian Medical Psychedelics Market Via Mind Medicine Australia
Via
Benzinga
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
February 27, 2023
Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and...
Via
Benzinga
Awakn's First Licensing Partnership Deal In Europe Involves Chain Of Portuguese Clinics
February 22, 2023
Awakn Life Sciences Corp. (OTCQB: AWKNF) has signed a licensing partnership agreement in Europe with a Portugal-based healthcare consortium currently operating in stealth mode.
Via
Benzinga
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
February 21, 2023
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and...
Via
Benzinga
Psychedelics For Alcohol Use Disorder: Awakn Opens European Clinic, FSD Launches R&D Program
February 14, 2023
Awakn Opens Fourth European Clinic, Norway Takes Center Stage
Via
Benzinga
Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More
February 13, 2023
Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More
Via
Benzinga
A New Way Of Delivering MDMA? Awakn And Tech Partner Are Set To Study Viability
February 09, 2023
Psychedelics biotech Awakn Life Sciences (OTCQB: AWKNF) has initiated a feasibility study of formulating and delivering MDMA through Catalent’s proprietary oral,
Via
Benzinga
Awakn Life Sciences Corp Shares Rally 77% After Earning ILAP Expedited Approval Pathway For Its Ketamine-Assisted AUD Therapeutic ($AWKNF)
February 09, 2023
Via
AB Newswire
Exposures
Product Safety
Awakn's Ketamine Treatment For Alcohol Use Disorder Awarded UK's Fast-Track Status
February 07, 2023
Awakn Life Sciences Corp. (OTCQB: AWKNF), a biotech company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), has been granted an Innovation Passport for...
Via
Benzinga
Awakn Life Sciences Corp Earns Global AUD Treatment Interest With A New Class Of Psychedelics-Based Therapeutic ($AWKNF)
February 07, 2023
Via
AB Newswire
Two New Studies On Classical Psychedelics: Grading Ketamine's Components, Tuning Down Psilocybin Dosing
January 24, 2023
Awakn’s First Study On Novel S-Ketamine Formulation To Assess Dissociative Effect
Via
Benzinga
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways
January 03, 2023
What a year for psychedelics!
Via
Benzinga
6 Largest Psychedelic Drug Stocks Were -20% In December
January 02, 2023
The Psychedelic Drug Stocks Index, which tracks the six largest psychedelic stocks researching the treatment of mental illnesses based on the use of one or more psychedelic substances, continued to...
Via
Talk Markets
Largest Psychedelic Stocks DOWN 8% Last Week; DOWN 22% So Far This Month
December 25, 2022
Today's article highlights the performance of the munKNEE Psychedelic Drug Stocks Index which tracks the six (6) largest psychedelic stocks researching the treatment of mental illnesses based on the...
Via
Talk Markets
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
December 19, 2022
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.
Via
Benzinga
Awakn Unveils Q3 Results, Touts Revenue Growth, R&D Progress, Commercial Plans
December 16, 2022
Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) shared its financial results and business highlights for a three-month period that ended Oct. 31, 2022. Financials showed:
Via
Benzinga
UK Supports Psychedelic Research With Phase 3 Trial In Federal Health Sites
December 13, 2022
Awakn Life Sciences Corp.
Via
Benzinga
Major Psychedelic Drug Stocks DOWN 9% Last Week; Now Down 51% YTD
December 11, 2022
Today's article highlights the performance of the largest psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of ten (10) different psychedelic substances.
Via
Talk Markets
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
December 06, 2022
Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and...
Via
Benzinga
Europe To Have Expanded Access To Psychedelic-Assisted Therapy With New Norway Clinic
December 03, 2022
Psychedelics biotech Awakn Life Sciences Corp.
Via
Benzinga
Psyched: Full-Dose & Microdosing LSD Studies, Research Scope For Fed Funding, Consumption Sites And More
November 29, 2022
LSD Research Ramps Up: Full-Dose & Microdosing For Alzheimer's Studies Led By Beckley Foundation Coming Soon
Via
Benzinga
Psychedelic Drug Stocks Index Has A Good Week
November 27, 2022
We track six psychedelic stocks researching the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances.
Via
Talk Markets
A Leading Ketamine Treatment Clinic For Alcoholism Is Expanding: Here's The Latest
November 23, 2022
A psychedelics R&D biotech company, known for providing novel treatments for addictions, is opening a new ketamine clinic.
Via
Benzinga
Psychedelic Drug Stocks Index Continued To Decline Last Week
November 20, 2022
This article highlights the performances of the 6 constituents in the munKNEE Psychedelic Drug Stocks Index last week and in the last 3 weeks and the extent to which each company is likely to encounter...
Via
Talk Markets
Psyched: Colorado Legalizes Psychedelics, NYC Treats Alcoholism With Ketamine, $30M Series A For Startup
November 15, 2022
Colorado Voters Approve Initiative To Legalize And Regulate Psychedelics
Via
Benzinga
EXCLUSIVE: New Partnership Brings Leading Psychedelic Protocol For Alcoholism Treatment To NYC
November 09, 2022
NYC-based clinics brand Nushama has partnered with Awakn Life Sciences (OTCQB: AWKNF), a clinical-stage psychedelics biotech company to bring
Via
Benzinga
Can Ketamine Treat Alcohol Addiction? In-Clinic Therapy Vs. Retreats
October 13, 2022
(Part four of a four-part series - Read part three)
Via
Benzinga
Can Ketamine Treat Alcohol Addiction? The Awakn Approach
October 10, 2022
(Part three of a four-part series)
Via
Benzinga
Psychedelic Drug Stocks Index Up Slightly This Week
October 08, 2022
There are 8 stocks in the munKNEE Psychedelic Drug Stocks Index and this article reveals how its constituents performed this week, in descending order, since the end of August and YTD.
Via
Talk Markets
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.